MedPath

SKYRIZI

SKYRIZI

Approved
DIN Number

02519283

Drug Class

Human

Market Date

Jun 1, 2022

Company
HC

Abbvie Corporation

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02519283
AIG Number0161390002
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription ,  Schedule D
A
ATC Code
L04AC18 RIZANKIZUMAB
Product Specifications
Dosage FormSolution
Route of AdministrationSubcutaneous
AHFS Classification84:06.28
Health Canada Classification

ACTIVE INGREDIENTS (1)

RISANKIZUMABActive
Strength: 150 MG / 1 ML
Monograph: RISANKIZUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.